Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

Inclusion Criteria: * Signs and symptoms suggestive of COVID-19 infection including cough or dyspnea * Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) test ≤7 days before randomization * Currently hospitalized or in an emergency department with planned hospitalization * Peripheral capillary oxygen saturation (SpO2) ≤93% on room air or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) \<300 at Screening Exclusion Criteria: * Simultaneous participation in any other clinical study incompatible with this one * Treatment with an antibody immunotherapy that is not standard of care for COVID-19 within 4 weeks of Screening * Requirement for mechanical ventilation or ECMO at Screening * Hypotension at Screening, defined as supine BP \<95 mm Hg systolic or \<55 mm Hg diastolic * Severe liver injury defined as AST or ALT ≥5x the upper limit of normal * Severe kidney failure defined as an estimated glomerular filtration rate (eGFR) \<30 mL/min * Any known immune deficiency * Pregnancy or breastfeeding